Investment Risk Analysis: NICOBLOC PLC

1. Risk Rating: HIGH

Justification: NICOBLOC PLC presents a constellation of serious financial and operational concerns that warrant a HIGH risk classification. The company has carried deeply negative shareholders' funds exceeding £2.4 million for the entire period under review, indicating chronic technical insolvency. Revenue has proven highly volatile—collapsing from £659,284 to £38,700 (a 94.1% decline) in the latest period—while cash reserves have repeatedly fallen to perilously low levels. The company's continued existence depends entirely on uncertain external funding arrangements that may not materialise.

2. Key Concerns

Concern 1: Chronic Technical Insolvency

Shareholders' funds have deteriorated consistently from approximately £-1.65 million (2018) to £-2.41 million (2025). This represents seven consecutive years of deeply negative equity, meaning accumulated losses vastly exceed any capital ever invested. The company is technically insolvent on a balance sheet basis and survives only through continued shareholder support and external funding. The strategic report explicitly acknowledges this dependency, stating the company "continues to rely on shareholder support and external funding to finance operations." Any withdrawal of this support would likely precipitate immediate failure.

Concern 2: Extreme Revenue Volatility and Cash Depletion

The revenue trajectory is alarming: £0 (2023), £659,284 (2024), then £38,700 (2025). This 94.1% decline cannot be characterised as normal business fluctuation—it suggests the business model is incapable of generating reliable, recurring income. Cash reserves have been critically low throughout the company's history: £83 (2018), £172 (2023), £315 (2024). Even the improvement to £23,623 in 2025 represents less than three months of operating costs at the current loss rate of £146,470 annually. The company is perpetually on the brink of cash exhaustion.

Concern 3: Questionable Asset Quality and Accounting Treatment

A significant discrepancy exists between reported net assets (£451,890) and shareholders' funds (£-2,414,564). This approximately £2.87 million gap strongly suggests that the "positive" net asset position is driven by capitalized intangible assets—patents, development costs, and computer software—rather than tangible commercial value. The accounts reference patents, development costs, and software as asset categories. Given the company's inability to generate consistent revenue from these assets over 17 years, their recoverability is highly doubtful. Capitalising development costs for a company with this trading history warrants scrutiny regarding whether the recognition criteria under FRS 102 are genuinely met.

3. Positive Indicators

• Regulatory Compliance: The company is filing accounts on time with no overdue filings. The latest accounts were made up to 17 March 2025 and are not overdue, suggesting the board maintains basic corporate governance standards.

• International Distribution Network: The strategic report references recently signed distribution agreements covering Australia, Japan, China, Singapore, Malaysia, Indonesia, Egypt, GCC, and Greece. If genuine, this represents a broad geographic footprint that could diversify revenue risk.

• Product Development Pipeline: The NicoPen product development and anticipated new patent filings suggest ongoing investment in intellectual property. The company maintains a clear product focus in smoking cessation/harm reduction—a sector with genuine public health demand.

4. Due Diligence Notes

1. Intangible Asset Valuation: Request a detailed breakdown of the £614,976 total assets, specifically the composition and valuation methodology for capitalized development costs, patents, and software. Assess whether impairment testing has been rigorous given the company's inability to commercialise these assets profitably over 17 years.

2. Going Concern Basis: Examine the auditor's report for any emphasis of matter or material uncertainty regarding going concern. Determine what specific funding commitments from shareholders underpin the going concern assumption, and whether these are legally binding or merely indicative.

3. US Government Contract Claims: Verify the status of the claimed US Veterans Association contract. The strategic report references "successful trials" and a prospective first order of "$1m," but these appear aspirational rather than contracted. Given the company's history of revenue shortfalls, assess the realistic probability of these revenues materialising.

4. $50m Loan Arrangement: Investigate the nature and credibility of the proposed "10-year loan of $50m interest-free but for a percentage of net profit." This structure is unusual for institutional lending and carries significant counterparty and execution risk. Determine whether a formal term sheet or binding commitment exists.

5. Shareholder Loan Structure: Analyse the composition of the £132,555 in current liabilities and any non-current liabilities. Determine what portion represents shareholder loans versus trade creditors, and whether shareholder loans are subordinated or carry repayment terms that could trigger insolvency.

6. Revenue Concentration: Given the dramatic revenue swing, investigate whether the FY2024 revenue of £659,284 represented a one-time transaction or licensing payment rather than recurring sales. This distinction is critical for assessing whether the business model is viable.

7. Auditor Quality: Nordens Audit Limited is a relatively small firm. For a PLC with international distribution claims and complex intangible assets, assess whether the audit firm has sufficient resources and sector expertise to provide robust oversight.